Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.64 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MLLT1 | Q03111 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448259 | 0.84 | RAB9A (0.67) | GRM5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5728908 | 0.82 | HSD17B1 (0.84) | HSD17B1HSD17B2MEN1KMT2ANPC1 | |
| SCHEMBL4188094 | 0.79 | GRM5 (0.63) | GRM5CYP2C9CYP2C19 | |
| SCHEMBL29683459 | 0.79 | HSD17B1 (0.62) | HSD17B1HSD17B2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL184352 | 0.79 | HSD17B1 (0.62) | HSD17B1HSD17B2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL29808134 | 0.79 | HSD17B1 (0.62) | HSD17B1HSD17B2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL1179871 | 0.78 | HSD17B1 (1.00) | HSD17B1HSD17B2MEN1KMT2ANPC1 | |
| SCHEMBL4322423 | 0.78 | CYP2A6 (0.60) | GRM5NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL7662534 | 0.78 | HSD17B1 (0.66) | HSD17B1HSD17B2MEN1KMT2ANPC1 | |
| SCHEMBL6831070 | 0.77 | HSD17B1 (0.60) | HSD17B1HSD17B2PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| WO-2005060961-A2 | TREATMENT OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRS) AND GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) | ASTRAZENECA AB (US) | 2005-07-07 | — | — | WO | claimed |
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1582519-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| CN-1379775-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2002-11-13 | — | — | CN | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | HSD17B1 37/4885HSD17B2 14/4885GRM5 582/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | HSD17B1 3578/4885HSD17B2 3250/4885GRM5 8/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | HSD17B1 3468/4885HSD17B2 3375/4885GRM5 1/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | HSD17B1 3578/4885HSD17B2 3250/4885GRM5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.